BMI RD
South and Central America Liposome Drug Delivery Market Forecast to 2027- COVID -19 Impact and Regional Analysis- by Product Type (Liposomal doxorubicin, Liposomal paclitaxel, Liposomal Amphotericin B, Others); Technology (Stealth liposome technology, Non- PEGylated liposome technology, DepoFoam Liposome Technology, Lysolipid Thermally Sensitive Liposome Technology); Application (Fungal diseases, Cancer therapy, pain management, Viral Vaccine), and Country
Pages: 118
Market Introduction
The Liposome are novel drug delivery system (NDDS), they are vesicular structures consisting of bilayers which form spontaneously when phospholipids are disappeared in water. They are microscopic vesicles in which an aqueous volume is entirely enclosed by a membrane composed of lipid bilayers.
Market Overview and Dynamics
The South and Central America Liposome Drug Delivery market is expected to reach US$ 206.29 million by 2027 from US$ 116.72 million in 2019. The market is anticipated to grow with a CAGR of 7.5 % from 2019 to 2027. Increasing Prevalence of chronic diseases, increasing demand for non-invasive drug delivery system along with rising R&D expenditures by pharmaceutical companies are some of the driving force of the market. Whereas, high cost associated with development of Non-invasive drug delivery system is about to hinder the market growth during forecast period.
Key Market Segments
In The liposome drug delivery market is mainly segmented on the basis of products, technology and applications. The products are liposomal doxorubicin, liposomal Paclitaxel. On basis of technology it is segmented as stealth liposome technology, Depofoam liposome technology and others. And the final segmentation is on the application such as its usage in cancer therapy, fungal diseases, and pain management.
Major Sources and Companies Listed
Some of the major primary and secondary sources for Liposome drug delivery market included in the report are Food and Drug Administration (FDA), World health Organization (WHO) and others.
Reasons to buy the report
SOUTH AND CENTRAL AMERICA LIPOSOME DRUG DELIVERY MARKET SEGMENTATION
By Product
By technology
By Application
Fungal diseases
By Country
Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 116.72 Million |
| Market Size by 2027 | US$ 206.29 Million |
| CAGR (2019 - 2027) | 7.5 % |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Product
|
| Regions and Countries Covered |
South and Central America
|
| Market leaders and key company profiles |
|
The South and Central America Liposome Drug Delivery Market is valued at US$ 116.72 Million in 2019, it is projected to reach US$ 206.29 Million by 2027.
As per our report South and Central America Liposome Drug Delivery Market, the market size is valued at US$ 116.72 Million in 2019, projecting it to reach US$ 206.29 Million by 2027. This translates to a CAGR of approximately 7.5 % during the forecast period.
The South and Central America Liposome Drug Delivery Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Liposome Drug Delivery Market report:
The South and Central America Liposome Drug Delivery Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Liposome Drug Delivery Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Liposome Drug Delivery Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)